Sumary of Nivolumab plus ipilimumab shows benefit in advanced prostate cancer subset:
- Nivolumab plus ipilimumab induced durable responses among a subset of men with metastatic castration-resistant prostate cancer, according to results of the phase 2 CheckMate 650 study published in Cancer Cell..
- Nivolumab plus ipilimumab induced durable responses among a subset of men with metastatic castration-resistant prostate cancer..
- “We had previously found that in response to ipilimumab [Yervoy, Bristol Myers Squibb] there was a significant increase in tumor-infiltrating T cells, as well as increased expression of compensatory inhibitory immune checkpoints, including PD-1 and PD-L1, within the prostate tumor microenvironment..
- The compensatory inhibitory pathways could account for the limited efficacy of ipilimumab in men with advanced prostate cancer,”.
- Padmanee Sharma, MD, PhD, professor in the department of genitourinary medical oncology and immunology at The University of Texas MD Anderson Cancer Center, told Healio..
- “Based on these findings and other data in animal models, we designed CheckMate 650 to evaluate the safety and efficacy of nivolumab [Opdivo, Bristol Myers Squibb] plus ipilimumab in men with metastatic castration-resistant prostate cancer.”.
- Current treatments for metastatic castration-resistant prostate cancer often fail to induce durable long-term responses..
- For this reason, Sharma and colleagues conducted a multicenter, open-label study that included 90 men (77.8% white) with metastatic castration-resistant prostate cancer who received 1 mg/kg nivolumab, which targets PD-1, plus 3 mg/kg ipilimumab, which targets CTLA-4, every 3 weeks for four doses, followed by 480 mg nivolumab monotherapy every 4 weeks….